arrow_back Trending Legislation
Share share

Faster FDA Review: Modernizing Human Cell and Tissue Product Regulations

This law aims to speed up and clarify the approval process for new therapies based on human cells and tissues (like regenerative medicine). It mandates the FDA to quickly respond to manufacturers' questions about product classification, potentially reducing the time it takes for treatments to reach the market. Citizens can expect clearer safety standards and potentially faster access to innovative medical treatments.
Key points
Establishes a 70-day deadline for the FDA to provide a preliminary, nonbinding opinion on how a specific cell or tissue product will be regulated.
Requires a public meeting to discuss and update key regulatory definitions, such as 'minimal manipulation' of tissue.
Mandates updating regulations within 12 months to reduce bureaucratic burdens on manufacturers while maintaining public health protection.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
The HCT/P Modernization Act of 2024
Print number: HR 8251
Sponsor: Rep. Crenshaw, Dan [R-TX-2]
Process start date: 2024-05-06
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Faster FDA Review: Modernizing Human Cell and Tissue Product Regulations

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 8251.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-05-06.

What are the main provisions?

Key points include:

  • Establishes a 70-day deadline for the FDA to provide a preliminary, nonbinding opinion on how a specific cell or tissue product will be regulated.
  • Requires a public meeting to discuss and update key regulatory definitions, such as 'minimal manipulation' of tissue.
  • Mandates updating regulations within 12 months to reduce bureaucratic burdens on manufacturers while maintaining public health protection.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Crenshaw, Dan [R-TX-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 8251

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health